210 related articles for article (PubMed ID: 37686697)
21. Concomitant Inhibition of FASN and SREBP Provides a Promising Therapy for CTCL.
Chi C; Harth L; Galera MR; Torrealba MP; Vadivel CK; Geisler C; Bonefeld CM; Nielsen PR; Bzorek M; Becker JC; Gjerdrum LMR; Ødum N; Woetmann A
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139650
[TBL] [Abstract][Full Text] [Related]
22. Killer cell immunoglobulin-like receptor expression delineates in situ Sézary syndrome lymphocytes.
Wechsler J; Bagot M; Nikolova M; Parolini S; Martin-Garcia N; Boumsell L; Moretta A; Bensussan A
J Pathol; 2003 Jan; 199(1):77-83. PubMed ID: 12474229
[TBL] [Abstract][Full Text] [Related]
23. Mycosis fungoides and Sézary syndrome.
Jonak C; Tittes J; Brunner PM; Guenova E
J Dtsch Dermatol Ges; 2021 Sep; 19(9):1307-1334. PubMed ID: 34541796
[TBL] [Abstract][Full Text] [Related]
24. Dysregulated synthesis of intracellular type 1 and type 2 cytokines by T cells of patients with cutaneous T-cell lymphoma.
Lee BN; Duvic M; Tang CK; Bueso-Ramos C; Estrov Z; Reuben JM
Clin Diagn Lab Immunol; 1999 Jan; 6(1):79-84. PubMed ID: 9874668
[TBL] [Abstract][Full Text] [Related]
25. Skin infiltrating NK cells in cutaneous T-cell lymphoma are increased in number and display phenotypic alterations partially driven by the tumor.
Scheffschick A; Nenonen J; Xiang M; Winther AH; Ehrström M; Wahren-Herlenius M; Eidsmo L; Brauner H
Front Immunol; 2023; 14():1168684. PubMed ID: 37691935
[TBL] [Abstract][Full Text] [Related]
26. Blocking the PCNA/NKp44 Checkpoint to Stimulate NK Cell Responses to Multiple Myeloma.
Iraqi M; Edri A; Greenshpan Y; Goldstein O; Ofir N; Bolel P; Abu Ahmad M; Zektser M; Campbell KS; Rouvio O; Gazit R; Porgador A
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563109
[TBL] [Abstract][Full Text] [Related]
27. Expression of immune checkpoint molecules programmed death protein 1, programmed death-ligand 1 and inducible T-cell co-stimulator in mycosis fungoides and Sézary syndrome: association with disease stage and clinical outcome.
Di Raimondo C; Rubio-Gonzalez B; Palmer J; Weisenburger DD; Zain J; Wu X; Han Z; Rosen ST; Song JY; Querfeld C
Br J Dermatol; 2022 Aug; 187(2):234-243. PubMed ID: 35194801
[TBL] [Abstract][Full Text] [Related]
28. The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin.
Moyal L; Feldbaum N; Goldfeiz N; Rephaeli A; Nudelman A; Weitman M; Tarasenko N; Gorovitz B; Maron L; Yehezkel S; Amitay-Laish I; Lubin I; Hodak E
PLoS One; 2016; 11(1):e0146115. PubMed ID: 26752418
[TBL] [Abstract][Full Text] [Related]
29. T-cell receptor beta variable region (V beta) usage in cutaneous T-cell lymphomas (CTCL) in comparison to normal and eczematous skin.
Potoczna N; Boehncke WH; Nestle FO; Küenzlen C; Sterry W; Burg G; Dummer R
J Cutan Pathol; 1996 Aug; 23(4):298-305. PubMed ID: 8864915
[TBL] [Abstract][Full Text] [Related]
30. New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications.
Luna DE; Shinohara MM
Curr Hematol Malig Rep; 2023 Jun; 18(3):83-88. PubMed ID: 37017872
[TBL] [Abstract][Full Text] [Related]
31. Identification of cell surface molecules characterizing human cutaneous T-cell lymphomas.
Nikolova M; Bagot M; Boumsell L; Bensussan A
Leuk Lymphoma; 2002 Apr; 43(4):741-6. PubMed ID: 12153159
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
[TBL] [Abstract][Full Text] [Related]
33. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Wong HK; Mishra A; Hake T; Porcu P
Br J Haematol; 2011 Oct; 155(2):150-66. PubMed ID: 21883142
[TBL] [Abstract][Full Text] [Related]
34. The Role of Tumor Microenvironment in Mycosis Fungoides and Sézary Syndrome.
Liu Z; Wu X; Hwang ST; Liu J
Ann Dermatol; 2021 Dec; 33(6):487-496. PubMed ID: 34858000
[TBL] [Abstract][Full Text] [Related]
35. The Ectopic Expression of Meiosis Regulatory Genes in Cutaneous T-Cell Lymphomas (CTCL).
Gantchev J; Martínez Villarreal A; Xie P; Lefrançois P; Gunn S; Netchiporouk E; Sasseville D; Litvinov IV
Front Oncol; 2019; 9():429. PubMed ID: 31214493
[TBL] [Abstract][Full Text] [Related]
36. Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma.
Van-de-Velde V; Zhou Y
J Cutan Med Surg; 2019; 23(3):319-327. PubMed ID: 30943788
[TBL] [Abstract][Full Text] [Related]
37. Gene expression profiling and immune cell-type deconvolution highlight robust disease progression and survival markers in multiple cohorts of CTCL patients.
Lefrançois P; Xie P; Wang L; Tetzlaff MT; Moreau L; Watters AK; Netchiporouk E; Provost N; Gilbert M; Ni X; Sasseville D; Wheeler DA; Duvic M; Litvinov IV
Oncoimmunology; 2018; 7(8):e1467856. PubMed ID: 30221071
[TBL] [Abstract][Full Text] [Related]
38. Localization of clonal T cells to the epidermis in cutaneous T-cell lymphoma.
Fivenson DP; Hanson CA; Nickoloff BJ
J Am Acad Dermatol; 1994 Nov; 31(5 Pt 1):717-23. PubMed ID: 7929915
[TBL] [Abstract][Full Text] [Related]
39. Cutaneous T-Cell Lymphoma: Optimizing Care in Patients Receiving Anti-CCR4 Monoclonal Antibody Mogamulizumab.
Tawa M; Kopp E; McCann S; Cantrell W
Clin J Oncol Nurs; 2019 Aug; 23(4):E73-E80. PubMed ID: 31322628
[TBL] [Abstract][Full Text] [Related]
40. Analysis of CTCL cell lines reveals important differences between mycosis fungoides/Sézary syndrome
Netchiporouk E; Gantchev J; Tsang M; Thibault P; Watters AK; Hughes JM; Ghazawi FM; Woetmann A; Ødum N; Sasseville D; Litvinov IV
Oncotarget; 2017 Nov; 8(56):95981-95998. PubMed ID: 29221181
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
